LRP2

bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Exercise, Department of Defense Serum Repository, Medicaid, University, Observational study, CPT, CD320, Marketing, Gastric lavage, Lung cancer, Research, BIAF, RNA, Lung, Military personnel, Small RNA, American Medical Association, Medicare, DOD, Congress, COVID-19, Patient, Physician, Flow cytometry, AMA, CFO, City, LRP2, Therapy, International Society, Pharmaceutical industry

Revenue for the second quarter of 2023 was $20,000, compared with $1,000 for the prior-year period.

Key Points: 
  • Revenue for the second quarter of 2023 was $20,000, compared with $1,000 for the prior-year period.
  • Research and development expenses were $335,000 for the second quarter of 2023, compared with $248,000 for the comparable period in 2022.
  • Clinical development expenses were $35,000 for the second quarter of 2023, compared with $28,000 for the second quarter of 2022.
  • Selling, general and administrative expenses were $1.4 million for the second quarter of 2023, compared with $409,000 for the comparable period in 2022.

bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium

Retrieved on: 
Thursday, June 15, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Vitamins, Supplements, Other Science, Research, Science, Clinical Trials, Sputum, Ruby Elzy, University, University of Massachusetts, Therapy, Senior, CD320, TCPP, Cancer, Lung cancer, RNA, DRS, BIAF, Cell, Lung, Bauta, Small RNA, Gene silencing, University of Massachusetts Chan Medical School, Flow cytometry, Sirna Therapeutics, LRP2, Death, Gene, Dietary supplement

Chan Medical School’s fifth annual RNA Therapeutics Symposium June 21-23, 2023, in Worcester, MA.

Key Points: 
  • Chan Medical School’s fifth annual RNA Therapeutics Symposium June 21-23, 2023, in Worcester, MA.
  • The RNA Therapeutics Institute at UMass leverages RNA biology and clinical research to develop new therapeutics for multiple diseases based on the fundamental mechanisms of cellular RNAs.
  • The vitamin B12 research follows the Company’s discovery that using small interfering RNA (siRNA) to knock down CD320 and LRP2 killed cancer cells in vitro without harming healthy cells.
  • bioAffinity Technologies’ noninvasive test for early-stage lung cancer, CyPath® Lung , incorporates TCPP to identify cell populations in sputum that indicate cancer is present in the lung.

bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

Retrieved on: 
Thursday, December 1, 2022
Research, Surgery, Medical Devices, Genetics, Biotechnology, Radiology, Health, Science, Oncology, Marketing, EST, Thomas D. Pollard, European Molecular Biology Organization, Laboratory, Lung, Gene, CD320, Brain, ASCB, University of Texas Southwestern Medical Center, University, Cell biology, Prostate, Society, Laboratory developed test, Sirna Therapeutics, LDT, EMBO, Therapy, Cell, Walter, LRP2, BIAF, Biology, Breast, Medical imaging, Research, D.C

Dr. Elzis recent research that will be presented next week at Cell Bio looks at why it works.

Key Points: 
  • Dr. Elzis recent research that will be presented next week at Cell Bio looks at why it works.
  • bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment.
  • OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells.
  • Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio.

bioAffinity Technologies Presents its Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

Retrieved on: 
Monday, December 6, 2021
Research, Genetics, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Science, Oncology, Research, EMBO, Lung, ASCB, Prostate, Cancer, LRP2, Technology, Sirna Therapeutics, Brain, Company, Diagnosis, Breast, University, Education, RNA interference, Laboratory, Therapy, COVID-19, Thomas D. Pollard, RNA, CD320, CST, Society, RNA transfection, Â, Medicine, Cell biology, Gene, European Molecular Biology Organization, Vaccine

bioAffinitys discovery of a fundamental vulnerability of cancer opens the way to new therapies that kill cancer without harm to normal tissue, Dr. Elzi said.

Key Points: 
  • bioAffinitys discovery of a fundamental vulnerability of cancer opens the way to new therapies that kill cancer without harm to normal tissue, Dr. Elzi said.
  • bioAffinity Technologies, Inc. ( www.bioaffinitytech.com ) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment.
  • The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells.
  • Research and optimization of its platform technology are conducted in bioAffinity Technologies laboratories at the University of Texas San Antonio.